Bile Acid HDCA Protects Bone Marrow Cells and Improves Bone Structure in Mice
A bile acid reduced aging-related changes in human bone marrow cells and improved bone structure in mice. Benefits in women remain unproven.
Summary
A bile acid called hyodeoxycholic acid, or HDCA, may help protect the cells that maintain bone after menopause. Researchers found lower blood levels of HDCA in women with postmenopausal osteoporosis than in healthy donors. Lower levels were associated with more aging-related changes and fat formation in bone marrow cells. Adding HDCA to cells collected from patients reduced these problems. In mice whose ovaries had been removed, oral HDCA improved bone structure. The proposed mechanism involves increasing estrogen receptor activity and helping cells clear damaged energy-producing components. This suggests a possible treatment strategy that does not require administering estrogen, but it is not evidence that HDCA supplements prevent fractures or treat osteoporosis in women. Human treatment trials are needed, and this summary is based on the abstract only.
Detailed Summary
After menopause, declining estrogen can shift bone marrow cells away from building bone and toward storing fat, while also promoting cellular aging. These changes contribute to osteoporosis and threaten mobility and independence. Researchers investigated whether hyodeoxycholic acid, a bile acid called HDCA, could protect these cells and help preserve bone structure.
The study combined comparisons of blood bile acids in women with postmenopausal osteoporosis and healthy donors, experiments using patient-derived bone marrow cells, and tests in mice whose ovaries had been removed. Researchers also used gene silencing, chemical inhibitors, gene activity analysis, and computer modeling to investigate how HDCA might influence cellular aging, fat formation, and mitochondrial maintenance.
Women with osteoporosis had lower circulating HDCA, with the largest reduction among the bile acids identified as different between groups. Lower levels were associated with more cellular aging and fat formation. Adding HDCA to patient-derived cells reduced these problems in a dose-dependent manner. In mice, oral HDCA restored circulating levels, improved deteriorated bone architecture, and activated related signaling in intestinal and bone tissues.
The proposed pathway starts with HDCA activating the bile acid receptor TGR5. This stimulates signaling that increases estrogen receptor production and promotes disposal of damaged mitochondria, the energy-producing structures inside cells. These findings suggest a potential approach to supporting bone cells without administering estrogen. However, involvement of estrogen receptor signaling means this mechanism should not be described as independent of the body's hormone pathways.
These results do not establish that HDCA treats osteoporosis in women. Human evidence was observational, while treatment benefits came from laboratory cells and mice. The abstract does not provide sample sizes, effect sizes, dosing details, or safety results. This summary is based on the abstract only. Clinical trials must establish dosing, safety, and fracture outcomes before HDCA could be considered alongside established osteoporosis prevention or treatment.
Key Findings
- Women with postmenopausal osteoporosis had lower serum HDCA; lower levels correlated with greater bone marrow cell senescence and fat formation.
- HDCA treatment reduced senescence and abnormal fat formation in patient-derived bone marrow cells in a dose-dependent manner.
- Mechanistic experiments implicated TGR5 signaling, increased estrogen receptor expression, and PINK1/Parkin-mediated clearance of damaged mitochondria.
- Oral HDCA improved bone architecture in ovariectomized mice; treatment benefits in women have not been demonstrated.
- These findings do not justify replacing established osteoporosis care with HDCA supplementation.
Methodology
The study combined human serum bile acid profiling, patient-derived bone marrow stromal cell experiments, and an ovariectomized mouse model. Mechanistic investigations included molecular docking, RNA sequencing, TGR5/ESR1 gene silencing, PKA inhibition, and chemically induced cellular senescence.
Study Limitations
This summary is based on the abstract only, which does not report sample sizes, quantitative effect sizes, detailed dosing, or safety findings. Human associations cannot establish causality, and benefits in cultured cells and ovariectomized mice may not translate to women. No human treatment or fracture-prevention benefit is established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: